In patients with type 2 diabetes, the combination of empagliflozin and metformin ameliorated liver steatosis, ALT levels, body weight, and glycated hemoglobin after a 6-month follow-up, as compared with the metformin monotherapy [68]. The gene discussed is GPT; the disease is fatty liver disease.